Intrinsiqq
Clover Health Investments, Corp. logo

Clover Health Investments, Corp. (CLOV) Insider Trading

Last 12 months

Insiders sold $8.82M and bought nothing on the open market.

88% of the selling was scheduled in advance under 10b5-1 plans. Director Carladenise Armbrister Edwards sold $230k on May 18, 19% of their stake, outside a plan. The last open-market buy by an executive or director was in Aug 2025.

Net open-market
−$8.82M
0 buys · 42 sales
Under a 10b5-1 plan
88%
of the value sold
Insiders who bought / sold
0 / 8
executives and directors
Last open-market buy
Aug 2025
Aug 13, 2025

Get an email when CLOV's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

  • Oct 2010b5-1 plan
    Karen Soares
    Chief Legal Officer · sold 19,275 at $4.66
    $90k
    1.2% of stake
  • Oct 1910b5-1 plan
    Jamie L. Reynoso
    CEO, Medicare Advantage · sold 4,066 at $4.41
    $18k
    0.1% of stake
  • Oct 1510b5-1 plan
    Andrew Toy
    Chief Executive Officer · sold 62,176 at $4.68
    $291k
    0.7% of stake
  • Oct 1510b5-1 plan
    Karen Soares
    Chief Legal Officer · sold 14,673 at $4.68
    $69k
    0.9% of stake
  • Oct 1510b5-1 plan
    Joseph Clay Thornton
    Interim CFO · sold 4,591 at $4.68
    $21k
    0.4% of stake
  • Oct 1510b5-1 plan
    Conrad Wai
    CEO, Counterpart Health · sold 23,627 at $4.68
    $111k
    1.1% of stake
  • Oct 1510b5-1 plan
    Jamie L. Reynoso
    CEO, Medicare Advantage · sold 18,273 at $4.68
    $86k
    0.7% of stake
  • Oct 710b5-1 plan
    Jamie L. Reynoso
    CEO, Medicare Advantage · sold 2,006 at $4.63
    $9k
    <0.1% of stake
  • Oct 510b5-1 plan
    Jamie L. Reynoso
    CEO, Medicare Advantage · sold 8,750 at $4.42
    $39k
    0.3% of stake
  • Oct 110b5-1 plan
    Andrew Toy
    Chief Executive Officer · sold 318,806 at $4.19
    $1.34M
    3.4% of stake
  • Sep 1710b5-1 plan
    Jamie L. Reynoso
    CEO, Medicare Advantage · sold 1,921 at $4.56
    $9k
    <0.1% of stake
  • Sep 1610b5-1 plan
    Joseph Frank Oldakowski
    VP OF FINANCE AND CONTROLLER · sold 3,170 at $4.64
    $15k
    1.1% of stake
  • Sep 1510b5-1 plan
    Conrad Wai
    CEO, Counterpart Health · sold 300,000 at $4.72
    $1.42M
    12% of stake
  • Sep 1510b5-1 plan
    Karen Soares
    Chief Legal Officer · sold 6,846 at $4.78
    $33k
    0.4% of stake
  • Sep 1510b5-1 plan
    Jamie L. Reynoso
    CEO, Medicare Advantage · sold 9,273 at $4.78
    $44k
    0.3% of stake
  • Sep 14No plan
    Joseph Frank Oldakowski
    VP OF FINANCE AND CONTROLLER · sold 20,000 at $5.16
    $103k
    6.7% of stake
  • Aug 1710b5-1 plan
    Joseph Clay Thornton
    Interim CFO · sold 17,775 at $4.39
    $78k
    1.4% of stake
  • Aug 1010b5-1 plan
    Andrew Toy
    Chief Executive Officer · sold 87,798 at $4.65
    $408k
    0.9% of stake
  • Jul 2010b5-1 plan
    Karen Soares
    Chief Legal Officer · sold 51,700 at $4.51
    $233k
    3.3% of stake
  • Jul 1710b5-1 plan
    Jamie L. Reynoso
    CEO, Medicare Advantage · sold 4,839 at $4.53
    $22k
    0.2% of stake
  • Jul 1510b5-1 plan
    Andrew Toy
    Chief Executive Officer · sold 62,711 at $4.67
    $293k
    0.7% of stake
  • Jul 1510b5-1 plan
    Conrad Wai
    CEO, Counterpart Health · sold 24,215 at $4.67
    $113k
    0.9% of stake
  • Jul 1510b5-1 plan
    Jamie L. Reynoso
    CEO, Medicare Advantage · sold 13,119 at $4.67
    $61k
    0.5% of stake
  • Jul 1510b5-1 plan
    Karen Soares
    Chief Legal Officer · sold 10,519 at $4.67
    $49k
    0.7% of stake
  • Jul 1510b5-1 plan
    Joseph Clay Thornton
    Interim CFO · sold 4,630 at $4.67
    $22k
    0.4% of stake
  • Jul 810b5-1 plan
    Jamie L. Reynoso
    CEO, Medicare Advantage · sold 2,384 at $4.68
    $11k
    <0.1% of stake
  • Jul 610b5-1 plan
    Jamie L. Reynoso
    CEO, Medicare Advantage · sold 6,229 at $5.26
    $33k
    0.2% of stake
  • Jul 110b5-1 plan
    Andrew Toy
    Chief Executive Officer · sold 313,476 at $5.32
    $1.67M
    3.2% of stake
  • Jun 1710b5-1 plan
    Jamie L. Reynoso
    CEO, Medicare Advantage · sold 2,360 at $4.78
    $11k
    <0.1% of stake
  • Jun 1610b5-1 plan
    Joseph Frank Oldakowski
    VP OF FINANCE AND CONTROLLER · sold 12,102 at $4.86
    $59k
    3.9% of stake
  • Jun 1510b5-1 plan
    Jamie L. Reynoso
    CEO, Medicare Advantage · sold 6,350 at $4.61
    $29k
    0.2% of stake
  • Jun 1510b5-1 plan
    Karen Soares
    Chief Legal Officer · sold 4,681 at $4.61
    $22k
    0.3% of stake
  • Jun 1110b5-1 plan
    Jamie L. Reynoso
    CEO, Medicare Advantage · sold 7,289 at $4.91
    $36k
    0.3% of stake
  • May 2810b5-1 plan
    Conrad Wai
    CEO, Counterpart Health · sold 220,426 at $3.99
    $879k
    7.9% of stake
  • May 18No plan
    Carladenise Armbrister Edwards
    Director · sold 67,160 at $3.42
    $230k
    19% of stake
  • May 13No plan
    Brady Patrick Priest
    CEO of Clover Care Services · sold 98,039 at $3.52
    $345k
    4.6% of stake
  • Mar 1810b5-1 plan
    Jamie L. Reynoso
    CEO, Medicare Advantage · sold 5,833 at $1.91
    $11k
    0.2% of stake
  • Mar 4No plan
    Brady Patrick Priest
    CEO of Home Care · sold 175,000 at $2.17
    $380k
    8.1% of stake
  • Jan 2010b5-1 plan
    Jamie L. Reynoso
    CEO, Medicare Advantage · sold 4,597 at $2.58
    $12k
    0.2% of stake
  • Jan 710b5-1 plan
    Jamie L. Reynoso
    CEO, Medicare Advantage · sold 2,102 at $2.53
    $5k
    <0.1% of stake
How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch CLOV, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Related stocks: Hospital & Medical Service Plans

Spot a number that looks wrong? Check it in CLOV's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing CLOV

Create a free account and get 14 days of Premium: every stock and every tool.

  • Unlimited stocks
  • Stock screener
  • Portfolio tracker
  • Editable DCF
  • Compare side by side
  • Unlimited alerts

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

SectorsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.